Physician profile
Nikhil Bhargava
NPI 1568649382
$10,602.17
in general payments reported to CMS, 2019-2025
36 companies · $2,269 in 2025
The $2,269 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $755 · 2021: $682 · 2022: $1,654 · 2023: $1,957 · 2024: $2,016 · 2025: $2,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,242.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,654.25 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,587.34 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,070.21 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $779.60 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $518.97 | 2019-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $475.04 | 2022-2025 | Ibsrela |
| Pfizer INC. | $389.79 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $373.93 | 2020-2023 | |
| Celgene Corporation | $344.97 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $341.78 | 2024-2025 | Zenpep |
| Regeneron Pharmaceuticals, INC. | $319.29 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.16 | 2019-2022 | |
| Genzyme Corporation | $235.93 | 2023-2025 | |
| Qol Medical, LLC | $171.85 | 2022-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $103.28 | 2023-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $93.84 | 2019-2024 | Rebyota |
| Capsovision, INC. | $78.20 | 2024 | Capsocam Plus |
| Redhill Biopharma INC. | $72.74 | 2020 | |
| Boston Scientific Corporation | $72.39 | 2020-2022 | |
| Shionogi INC | $62.70 | 2019 | |
| Celltrion USA INC. | $62.43 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $60.72 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $57.31 | 2020-2025 | |
| Mauna Kea Technologies, INC. | $53.17 | 2021 | |
| Lilly USA, LLC | $51.71 | 2024-2025 | Omvoh |
| Ethicon US, LLC | $41.31 | 2020 | |
| Braintree Laboratories, INC. | $39.05 | 2021-2025 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $35.05 | 2025 | Rezdiffra |
| Novo Nordisk INC | $34.95 | 2022-2025 | Wegovy |
| Echosens North America, INC. | $22.67 | 2024 | Fibroscan |
| Teleflex LLC | $21.90 | 2023 | Arrow |
| Ucb, INC. | $21.03 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.36 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $18.57 | 2021 | |
| Concordia Pharmaceuticals INC. | $15.49 | 2019 | |
| Romark Laboratories, Lc | $6.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.